<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563017</url>
  </required_header>
  <id_info>
    <org_study_id>KW / EX / 04 - 038</org_study_id>
    <secondary_id>HARECCTR0500047</secondary_id>
    <nct_id>NCT00563017</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone</brief_title>
  <official_title>Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceutica N.V., Belgium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, tolerability and safety of patients on
      long-acting Risperidone microshpheres injection. The major advantage of long-acting injection
      over oral medication is facilitation of compliance in medication taking. Non-compliance is
      very common among schizophrenic and is a frequent cause of relapse.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2004</start_date>
  <completion_date type="Anticipated">November 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy/ Clinical Global Impression</measure>
    <time_frame>Week 0, 4, 8,12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Personal and Social Performance Scale</measure>
    <time_frame>Week 0, 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Extrapyramidal Symptom</measure>
    <time_frame>Week 0, 4, 8,12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>+Quality of life SF-36</measure>
    <time_frame>Week 0,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assoicated with injection VAS</measure>
    <time_frame>Week 0, 4, 8, 12</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Schizophrenia, Catatonic</condition>
  <condition>Schizophrenia, Disorganized</condition>
  <condition>Schizophrenia, Paranoid</condition>
  <condition>Schizophrenia</condition>
  <condition>Psychotic Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long-acting Risperidone microspheres injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with schizophrenia or another psychotic disorder according to DSM IV criteria
             who requires long term antipsychotic therapy

          -  Currently treated with either an atypical antipsychotic, other than risperidone, a
             conventional depot antipsychotic or oral conventional antipsychotic

          -  Subject has been symptomatically stable on a stable dose of an antipsychotic the last
             month

          -  Subject and/or patient's relative, guardian or legal representative has signed the
             informed consent form

        Exclusion Criteria:

          -  First antipsychotic treatment ever

          -  On clozapine during the last 3 month

          -  Serious unstable medical condition

          -  History or current symptoms of tardive dyskinesia

          -  History of neuroleptic malignant syndrome

          -  Pregnant or breast-feeding female

          -  Female patient of childbearing potential without adequate contraception.

          -  Participation in an investigational drug trial in the 30 days prior to selection

          -  Known intolerance/non-responder to risperidone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Wing King Lee, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yaumatei Psychiatric Center, Kwai Chung Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wing King Lee, Dr</last_name>
    <phone>(852) 2388 8559</phone>
    <phone_ext>269</phone_ext>
    <email>drwklee@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kwai Chung Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gloria FY Chan, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-ming Chan, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent WH Chan, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tin-sung Tam, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ekg.org.hk/HAREC-CTR/RegistryDisplay2.jsp?HARECID=HARECCTR0500047</url>
    <description>HAREC Clinical Trial Registry</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <keyword>Catatonic Schizophrenia</keyword>
  <keyword>Disorganized Schizophrenia</keyword>
  <keyword>Paranoid Schizophrenia</keyword>
  <keyword>Undifferentiated Schizophrenia</keyword>
  <keyword>Schizo-affective disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Catatonia</mesh_term>
    <mesh_term>Schizophrenia, Paranoid</mesh_term>
    <mesh_term>Schizophrenia, Disorganized</mesh_term>
    <mesh_term>Schizophrenia, Catatonic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

